PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Wednesday, May 14th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock opened at $1.08 on Tuesday. PDS Biotechnology has a fifty-two week low of $0.85 and a fifty-two week high of $4.29. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.33 and a quick ratio of 2.33. The firm has a market capitalization of $49.37 million, a P/E ratio of -1.15 and a beta of 0.95. The company’s 50 day moving average price is $1.36 and its two-hundred day moving average price is $1.33.

Analyst Upgrades and Downgrades

PDSB has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of PDS Biotechnology in a research note on Tuesday, July 1st. Wall Street Zen downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.